The Pharma Intelligence Awards Japan 2022 winners have now been announced

The 2022 Pharma Intelligence Awards winners by category:

• Best New Drug: Fujifilm Toyama Chemical, Lutathera for neuroendocrine tumors - sponsored by CMIC Group
• Licensing Deal of the Year: Sosei Heptares with Neurocrine Biosciences for novel muscarinic receptor agonists    
• Biotech Company of the Year (Private): PRISM Biolab - Sponsored by Avance Clinical
• Biotech Company of the Year (Public): Rakuten Medical (Rakuten Group Inc.’s equity accounted affiliate) - Sponsored by Avance Clinical
• Best Contract Research Organization: CMIC Group 
• Executive of the Year: Chris Cargill, executive officer, chief financial officer, Sosei Heptares (position at time of nomination)
• Pharma Company of the Year: Daiichi Sankyo
• Lifetime Achievement Award: Dr. Toichi Takenaka - Sponsored by ICON

Tokyo, Japan – September 3rd, 2022 - Last night, the winners of the inaugural Pharma Intelligence Awards Japan 2022 were announced at the Palace Hotel in Tokyo. The Awards recognize outstanding advancements and innovations in Japanese pharma and biotech, highlighting Japan’s integral role in the global healthcare market.

Over 150 leading innovators attended the prestigious event to discover new opportunities and reflect on life-changing accomplishments made over the previous year.

The Pharma Intelligence Awards Japan 2022 span 8 categories, covering a spectrum of key biotech activities and advances in global healthcare and innovation. 

Best New Drug: Fujifilm Toyama Chemical’s Lutathera for neuroendocrine tumors - sponsored by CMIC Group

Approved for use in neuroendocrine tumors, through peptide receptor radionuclide therapy, Lutathera is set to become a new treatment option; providing an antitumor effect in patients, including those who are non-responders to conventional treatments.

Licensing Deal of the Year: Sosei Heptares with Neurocrine Biosciences for novel muscarinic receptor agonists

Sosei Heptares and Neurocrine Biosciences engaged in a successful strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists for schizophrenia, dementia and other neuropsychiatric disorders.

Biotech Company of the Year (Private): PRISM Biolab - Sponsored by Avance Clinical

Based in Japan, PRISM BioLab is a biotechnology company with proprietary small molecule drug discovery technology PepMetics®; this innovative platform enables the discovery of hit compounds for targets that were previously difficult to discover.

Biotech Company of the Year (Public): Rakuten Medical (Rakuten Group Inc.’s equity accounted affiliate)

Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™ platform. In 2021, the company launched the world-first drugs, Akalux® and BioBlade®, to treat unresectable locally advanced or recurrent head and neck cancer.

Best Contract Research Organization: CMIC Group

Established in 1992, CMIC Group is the largest clinical CRO in Japan with a global footprint, providing end-to-end solutions for the entire drug development value chain.

Executive of the Year: Chris Cargill, executive officer, chief financial officer, Sosei Heptares (position held at time of nomination)

Honored by his peers for his exceptional work, Chris Cargill was instrumental in a large-scale re-licensing agreement of their muscarinic agonist portfolio, and secured substantial corporate fundraising for Sosei Heptares.

Pharma Company of the Year: Daiichi Sankyo Group

Daiichi Sankyo is one of the leading global pharma innovators, with a clear focus on R&D, specifically within highly effective antibody-drug conjugates (ADCs). The company continues to leverage world-class, innovative science to deliver transformational outcomes in cancer.

Lifetime Achievement Award: Dr. Toichi Takenaka - Sponsored by ICON

Dr. Takenaka has a highly distinguished career spanning 60 years across R&D, global development and senior management, including as president and CEO of Yamanouchi Pharmaceutical, and inaugural president and CEO, and later co-chairman, of Astellas Pharma. He was closely involved in the development of several important new drugs, including blockbuster tamsulosin, and has held university professorships and key industry positions, including chairman of the Federation of Pharmaceutical Manufacturers’ Associations of Japan.

Dr Takenaka has received multiple awards including Japan’s Medal of Honor with Purple Ribbon and Order of the Rising Sun, Gold and Silver Star.

Ian Haydock, Editor-in-Chief, APAC, said: “We’re delighted to announce the winners of the first Pharma Intelligence Awards Japan for 2022. It’s been fantastic to recognize the achievements made over the past year in Japan within the biopharma and global healthcare market. Congratulations to all of this year’s winners and a big thank you to our nominees, sponsors and judges who contributed to a great event. We look forward to celebrating again next year!”

pharmaintelligence.informa.com/events/awards/japan-awards-2022 

About Pharma Intelligence
Trusted by over 3,000 of the world’s leading pharmaceutical companies, CROs, medtech and biotech organizations, and healthcare service providers, the Pharma Intelligence suite of intelligence solutions delivers vital, accurate, and timely intelligence about the drug development pipeline to pharmaceutical and biomedical decision makers around the world.

At Pharma Intelligence, global teams of subject area experts follow and analyze key diseases, clinical trials, drug approvals and R&D activities as part of the breadth and depth of data available to customers.